Focus: Becton Dickinson is a $19.4B global medical device and pharmaceutical company headquartered in Franklin Lakes, NJ, with 50,000+ employees serving healthcare systems, life sciences, and diagnostic markets.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Hot — 991 jobs added in 30d
Net +588 (991 new, 403 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 238 affected
Source: state DOL filings via Big Local News
Becton Dickinson offers scale and stability for medical device and healthcare operations professionals, but the combination of recent layoffs, single-product revenue dependence, and weak pipeline depth makes it a cautious choice for pharma scientists seeking innovation or long-term job security.
Core revenue driver and anchor product; oral rinse formulation with established clinical use in plaque and bacterial reduction for periodontal care.
Help build intelligence for Becton Dickinson
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Becton Dickinson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Patent expiration approaching October 2027 represents significant revenue cliff risk for this foundational product.
Surgical antiseptic product nearing LOE; part of broad antimicrobial portfolio.
Combination antiseptic swab for surgical site preparation; part of ChloraPrep/Prevantics family.
Ready-to-use applicator formulation with patent expiration April 2027; key surgical prep product.
Multi-application swab formulation for surgical antisepsis in the ChloraPrep portfolio.
Broader-spectrum chlorhexidine formulation; legacy antiseptic brand.
Alternative swab formulation in the Prevantics line; surgical antiseptic.
Single-step applicator variant for surgical skin antisepsis.
Flagship surgical prep product with patent cliff April 2027; significant revenue erosion expected.
4 discontinued, 11 duplicate formulations not shown
Becton Dickinson Is Down 30% From Its 52-Week High. Is It Still a Buy in 2026? - TIKR.com
Becton Dickinson Is Down 30% From Its 52-Week High. Is It Still a Buy in 2026? TIKR.com
Becton Dickinson stock (US0718131099): Earnings update and long-term healthcare demand - AD HOC NEWS
Becton Dickinson stock (US0718131099): Earnings update and long-term healthcare demand AD HOC NEWS
Healthcare suppliers bullish on plastics demand tied to injectable drugs - Plastics News
Healthcare suppliers bullish on plastics demand tied to injectable drugs Plastics News
Becton Dickinson Stock (US0718131099): Analyst Upgrade to Buy on GLP-1 Demand Boost - AD HOC NEWS
Becton Dickinson Stock (US0718131099): Analyst Upgrade to Buy on GLP-1 Demand Boost AD HOC NEWS
Becton Dickinson raises 2026 profit forecast on drug delivery devices demand - ETPharma.com
Becton Dickinson raises 2026 profit forecast on drug delivery devices demand ETPharma.com
Becton Dickinson raises annual profit forecast on strength in drug delivery devices - MSN
Becton Dickinson raises annual profit forecast on strength in drug delivery devices MSN
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via
Recent peer-reviewed publications with author affiliations at this company
Treating native arteries, bypasses and in-stent-restenosis with rotational athero-thrombectomy - two-year results from the Rotarex-PMCF trial.
Design Differences and Usability Risks in GLP-1 Pen Injectors: A Comparative Study of a Generic and Reference Device.
Recent layoffs centered at the Franklin Lakes headquarters and West Coast operations signal active cost reduction likely tied to revenue cliff concerns; job security risk is elevated despite ongoing hiring in operational roles.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo